美国 · SEC FORM 4
Xencor Inc
XNCR · Nasdaq · CIK 0001326732 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
13 同一窗口内观察到的 Form 4 交易行
5 sales · 8 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-02-13 · GORMAN KEVIN CHARLES.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 16,368,875
- 上期报告
- 15,751,444
- 日均成交量
- 1,618,765
- 回补天数
- 10.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-02-13 | GORMAN KEVIN CHARLES | 买入 (P) | Common Stock | 53 | USD 19.12 | USD 1,013 | SEC 申报 ↗ |
Form 4 申报证据
35 transaction lines in the latest 365-day window; 193 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Feigal Ellen | 卖出 (S) | Common Stock | 6,843 | USD 13.06 | USD 89,370 | SEC 申报 ↗ |
| 2026-06-16 | SIMPSON TODD E | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | RANIERI RICHARD J | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Feigal Ellen | 卖出 (S) | Common Stock | 6,843 | USD 13.06 | USD 89,370 | SEC 申报 ↗ |
| 2026-06-16 | SIMPSON TODD E | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | RANIERI RICHARD J | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Montgomery Alan Bruce | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Klencke Barbara | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | GUSTAFSON KURT A | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | GORMAN KEVIN CHARLES | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Feigal Ellen | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-16 | Deshaies Raymond Joseph | 奖励／授予 (A) | Common Stock | 10,302 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-15 | RANIERI RICHARD J | 卖出 (S) | Common Stock | 5,474 | USD 12.31 | USD 67,385 | SEC 申报 ↗ |
| 2026-06-15 | Montgomery Alan Bruce | 卖出 (S) | Common Stock | 5,064 | USD 12.31 | USD 62,338 | SEC 申报 ↗ |
| 2026-06-15 | GUSTAFSON KURT A | 卖出 (S) | Common Stock | 5,474 | USD 12.31 | USD 67,385 | SEC 申报 ↗ |
| 2026-06-15 | GORMAN KEVIN CHARLES | 卖出 (S) | Common Stock | 7,527 | USD 12.31 | USD 92,657 | SEC 申报 ↗ |
| 2026-04-10 | Cornelissen Bart Jan | 卖出 (S) | Common Stock | 3,499 | USD 12.29 | USD 43,003 | SEC 申报 ↗ |
| 2026-03-06 | Eckert Celia | 卖出 (S) | Common Stock | 1,767 | USD 11.02 | USD 19,472 | SEC 申报 ↗ |
| 2026-03-06 | Desjarlais John R | 卖出 (S) | Common Stock | 2,502 | USD 11.02 | USD 27,572 | SEC 申报 ↗ |
| 2026-03-06 | Dahiyat Bassil I | 卖出 (S) | Common Stock | 6,606 | USD 11.02 | USD 72,798 | SEC 申报 ↗ |
| 2026-03-05 | Eckert Celia | 卖出 (S) | Common Stock | 3,244 | USD 11.25 | USD 36,495 | SEC 申报 ↗ |
| 2026-03-05 | Desjarlais John R | 卖出 (S) | Common Stock | 4,118 | USD 11.25 | USD 46,328 | SEC 申报 ↗ |
| 2026-03-05 | Dahiyat Bassil I | 卖出 (S) | Common Stock | 14,870 | USD 11.25 | USD 167,288 | SEC 申报 ↗ |
| 2026-03-05 | Cornelissen Bart Jan | 卖出 (S) | Common Stock | 2,517 | USD 11.25 | USD 28,316 | SEC 申报 ↗ |
| 2026-03-03 | Eckert Celia | 卖出 (S) | Common Stock | 1,492 | USD 11.90 | USD 17,755 | SEC 申报 ↗ |
| 2026-03-03 | Desjarlais John R | 卖出 (S) | Common Stock | 2,663 | USD 11.90 | USD 31,690 | SEC 申报 ↗ |
| 2026-03-03 | Dahiyat Bassil I | 卖出 (S) | Common Stock | 6,758 | USD 11.90 | USD 80,420 | SEC 申报 ↗ |
| 2026-03-02 | Eckert Celia | 奖励／授予 (A) | Common Stock | 18,680 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Desjarlais John R | 奖励／授予 (A) | Common Stock | 24,907 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Dahiyat Bassil I | 奖励／授予 (A) | Common Stock | 97,291 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | Cornelissen Bart Jan | 奖励／授予 (A) | Common Stock | 19,458 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-23 | Desjarlais John R | 期权行权／转换 (M) | Common Stock | 5,322 | USD 12.51 | USD 66,578 | SEC 申报 ↗ |
| 2025-12-22 | Desjarlais John R | 期权行权／转换 (M) | Common Stock | 6,311 | USD 12.51 | USD 78,951 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | XNCR |
| CIK | 0001326732 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 193 transaction lines from 2020-01-06 to 2026-06-18 1 P purchase lines · 92 S sale lines · 100 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.